Zenas Wins Dismissal Of IPO Suit Over R&D Spending Claims
A Massachusetts federal judge has permanently dismissed an investor suit alleging Zenas BioPharma hid how quickly it was spending money before its 2024 initial public offering, saying the company warned investors...To view the full article, register now.
Already a subscriber? Click here to view full article